The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Two points. 737 is in an a space that promises, if successful, to lengthen the life or perhaps or cure people who are inflicted with terrible cancers with no known cure. Many on here, including a brother of mine, was such a person. Those who research and and contribute the most are liable to be targeted. Thoth was attacked on a regular basis. SOG is now in that position. There has been excellent discussions from top class posters recently, the subtle attack is designed to disrupt.
Interesting Fanti.While assessing and evaluating are interchangeable, it would be possible that assessing would refer to the standard of any proposal from a pharma while evaluating might include a comparison study of proposals to find the the one that best suits Sareum and ICF.
The narrative that 737 was returned because it did not cut the mustard has been proven false. That is the fundamental outcome. What happens next, sale or licence is up to CPF in consultation with Sareum. Its a positive RNS and with such triple therapy effacy it surely is just a matter of time until the options are evaluated and a sale or licence is negotiated.
Agree Celtic, SOGs posts on CHK1 737 are excellent. Very
M uch like your post Celtic also.
To recap.
Low tox, targeting certain late stage incurable cancers with apparently really impressive results and oral application when used in combo. This is extraordinary. We must also remember anogenatil was quite successful pre combo. Acrivon CHKI, with tox issues, being resurrected on the basis of 737 combo results. We are really in a good space. Imagine the cue is lengthening.
Excellent discussion this last while on 737. Really is looking like the real deal in terms of combo. Like SOG's estimated value of 750 mil. Would be truly transformative for the Company and for us investors. Would not like it going to any pharma that might sit on it or strangle it to protect some drug they have, can happen. Cancer sufferers with little other alternative hope deserve better.
Buying pretty incessant for a week and a half. By the way, on a point of order, hope whoever bought 23 shares at 108.9999 gets the precise change back. Only fair. That also goes, even more so to those individuals who sold 2 shares today. Only fair.
I know a type of trade chart was posted recently by one of our helpful posters, however if it walks like a duck, swaks like a duck, looks like a duck, poops like a duck and flies like a duck, then for ducks sake, it's a bleeding duck. It's a buy and it should have pushed the sp north.
Bill, good research there. Very reassuring, for me in any case, is the assertion that CPF get a royalty free to do whatever they want with it, including licencing onwards, a perpetual license to this new IP. I presume this includes the two paents that HBD found. That's my take on it, sounds like ownership?
Celtic i8007, think we are all relieved, reassured and feeling an awful lot better about our investment in Sareum. It's been a long stretch from SRA 737 being handed back and then the CTA delay. We have finally emerged in both areas and sra looking really promising. The glorious uncertainties of life. It was tough.
Blastoid 7. I believe that consolidation on AIM generally end up negative. I've been in one before that certainly did not work out. I'm sure PSC 1954 will give you SP response when he recovers from what must have been a tough and long day with weather and transport difficulties. The wisdom here is that it was to attract institutions, which did not happen. In a fun y way I like the idea that the pi's have control which means that the BOD have to take their views seriously. Thoth once went close to convening an EGM in times past because of dissatisfaction at the time. I was personally against consolidation, but we are where we are as they say.
Thank you. to all who attended, especially PSC1954 who fed back. Looks like the
BOD were willing to answer straight questions that were put to them. It's a good day for genuine holders considering some were very happy to dance on what they thought and hoped was the Company's, and by extension, shareholders grave.
We are in a good place now to progress successfully with 1801 and Sra737. Great analysis and teasing out of issues by many on here today. We'll done all as we look forward expectantly to an exciting and prosperous year ahead.
It would be wonderful to reach a destiny that will hopefully bring hope and cures to so many that could benefit from Sareum's pipeline in cancer and autoimmune conditions.
Agree, appreciate those who attended and and it was interesting and worthwhile what was devulged, and must say with a smile price sensitive as the RNS had people worried. Outcome from aprox 17% down at one stage to 10% up now and I have a feeling that the rerate has begun as the pipeline is tremendous.
There's an outright gobshyte over on the advfn board whose vindictivnes knows no bounds. He appeared on this bb for a while recently. He gloated after thisthis morning's RNS that the sp was heading for zero. The ultimate c womble, a total idiot. He goes by the user name love peace harmony. I'd say his Mrs, if he has one and knows about him has kicked him out for good. Wonder whether he will reappear, with a different username to blight this bb again.
Good post Lazarus2. Looks like the scar is over. Data and results not queried. Just data collection process for compliance. That's beyond expectations. SRA about to be returned and in discussions already happening Ré. Licensing.
Wow, what a relief
First well done the positive posters on here who are researching and contradicting the endless procession of doom and gloomers, in particular to those whose motive is to thrash the company regardless so that they can buy in cheaper. That the majority are loosing serious money is irrelevant to them. Narrcacistic sociopaths.
Tomorrow is pivotal and the BOD must provide clarity on the cause of delay, whether or when a resubmission has been sent and time frame for response. Good luck all genuine holders, we deserve it. Might be worth querying progress report on 1802 as it is presumably going through the same preclinical trials as 1801. We have a world quality pipeline which includes SRA737, lucky to get it back. Come on Sar.
As CHK1 inhibition can be overcome by blocking the pathways by using certain other pathway inhibitors, as pointed out by SOG in his post, how do you put a value on SRA737, how huge can it be when it can be effective as a triple combo in a range of other cancers, including ovarian and breast cancer that develop such a a resistance. And is 737 not applicable in 50 % of cancers. Good that it is coming home.